FDA, Hims and peptide
Digest more
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk.
Hims & Hers Health, Inc. surges after securing a partnership with Novo Nordisk, resolving legal and regulatory overhangs tied to compounded GLP-1s. HIMS's long-term platform thesis centers on becoming the go-to digital health platform, leveraging ...
From connected fitness and cycle tracking to meal delivery and glucose monitoring, Hims & Hers subscribers now have ten ways to support their whole-body health Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced ...
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiative ...
Hims & Hers Health (HIMS) added ~7% in the premarket on Thursday after announcing an agreement to acquire Eucalyptus, an Australian digital health provider, in a cash and stock transaction valued at up to $1.15B. With an annual revenue run rate exceeding $ ...
Telehealth companies including Hims & Hers Health Inc. and Noom Inc. urged a panel of experts to recommend legalizing a handful of popular peptides, while calling for more oversight and the creation of a system to report side effects.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9,